b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31298542</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>10</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>10</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1520-4804</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>62</Volume>\n                    <Issue>15</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>08</Month>\n                        <Day>08</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of medicinal chemistry</Title>\n                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>7264-7288</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.9b00891</ELocationID>\n            <Abstract>\n                <AbstractText>A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, <b>A12</b>, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure-activity relationship of compound <b>A12</b>, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative <b>E22</b>. <b>E22</b> showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound <b>E22</b> also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound <b>E22</b> could significantly inhibit the phosphorylation of proteins downstream of Akt kinase in cells and tumor tissue from the xenograft model.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Dong</LastName>\n                    <ForeName>Xiaowu</ForeName>\n                    <Initials>X</Initials>\n                    <Identifier Source="ORCID">0000-0002-2178-4372</Identifier>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhan</LastName>\n                    <ForeName>Wenhu</ForeName>\n                    <Initials>W</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Mengting</ForeName>\n                    <Initials>M</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Che</LastName>\n                    <ForeName>Jinxin</ForeName>\n                    <Initials>J</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dai</LastName>\n                    <ForeName>Xiaoyang</ForeName>\n                    <Initials>X</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wu</LastName>\n                    <ForeName>Yizhe</ForeName>\n                    <Initials>Y</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xu</LastName>\n                    <ForeName>Lei</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhou</LastName>\n                    <ForeName>Yubo</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Yanmei</ForeName>\n                    <Initials>Y</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tian</LastName>\n                    <ForeName>Tian</ForeName>\n                    <Initials>T</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cheng</LastName>\n                    <ForeName>Gang</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmaceutical Science , Zhejiang Chinese Medical University , Hangzhou 311402 , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jin</LastName>\n                    <ForeName>Zegao</ForeName>\n                    <Initials>Z</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Jia</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shao</LastName>\n                    <ForeName>Yanfei</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy , Zhejiang Provincial People\'s Hospital , Hangzhou 310014 , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>He</LastName>\n                    <ForeName>Qiaojun</ForeName>\n                    <Initials>Q</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yang</LastName>\n                    <ForeName>Bo</ForeName>\n                    <Initials>B</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Weng</LastName>\n                    <ForeName>Qinjie</ForeName>\n                    <Initials>Q</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hu</LastName>\n                    <ForeName>Yongzhou</ForeName>\n                    <Initials>Y</Initials>\n                    <Identifier Source="ORCID">0000-0001-7349-4062</Identifier>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>24</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Med Chem</MedlineTA>\n            <NlmUniqueID>9716531</NlmUniqueID>\n            <ISSNLinking>0022-2623</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000072237">ERG1 Potassium Channel</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C000606913">KCNH2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>67I85E138Y</RegistryNumber>\n                <NameOfSubstance UI="C032727">piperidine</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000072237" MajorTopicYN="N">ERG1 Potassium Channel</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045325" MajorTopicYN="N">HCT116 Cells</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>6</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31298542</ArticleId>\n            <ArticleId IdType="doi">10.1021/acs.jmedchem.9b00891</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'